Cargando…
Pilot Quality-Assurance Study of a Third-Generation Batch-Mode Clinical-Scale Automated Xenon-129 Hyperpolarizer
We present a pilot quality assurance (QA) study of a clinical-scale, automated, third-generation (GEN-3) (129)Xe hyperpolarizer employing batch-mode spin-exchange optical pumping (SEOP) with high-Xe densities (50% natural abundance Xe and 50% N(2) in ~2.6 atm total pressure sourced from Nova Gas Tec...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8879294/ https://www.ncbi.nlm.nih.gov/pubmed/35209116 http://dx.doi.org/10.3390/molecules27041327 |
_version_ | 1784658864534192128 |
---|---|
author | Birchall, Jonathan R. Chowdhury, Md Raduanul H. Nikolaou, Panayiotis Chekmenev, Yuri A. Shcherbakov, Anton Barlow, Michael J. Goodson, Boyd M. Chekmenev, Eduard Y. |
author_facet | Birchall, Jonathan R. Chowdhury, Md Raduanul H. Nikolaou, Panayiotis Chekmenev, Yuri A. Shcherbakov, Anton Barlow, Michael J. Goodson, Boyd M. Chekmenev, Eduard Y. |
author_sort | Birchall, Jonathan R. |
collection | PubMed |
description | We present a pilot quality assurance (QA) study of a clinical-scale, automated, third-generation (GEN-3) (129)Xe hyperpolarizer employing batch-mode spin-exchange optical pumping (SEOP) with high-Xe densities (50% natural abundance Xe and 50% N(2) in ~2.6 atm total pressure sourced from Nova Gas Technologies) and rapid temperature ramping enabled by an aluminum heating jacket surrounding the 0.5 L SEOP cell. (129)Xe hyperpolarization was performed over the course of 700 gas loading cycles of the SEOP cell, simulating long-term hyperpolarized contrast agent production in a clinical lung imaging setting. High levels of (129)Xe polarization (avg. %P(Xe) = 51.0% with standard deviation σ(P)(Xe) = 3.0%) were recorded with fast (129)Xe polarization build-up time constants (avg. T(b) = 25.1 min with standard deviation σ(T)(b) = 3.1 min) across the first 500 SEOP cell refills, using moderate temperatures of 75 °C. These results demonstrate a more than 2-fold increase in build-up rate relative to previously demonstrated results in a comparable QA study on a second-generation (GEN-2) (129)Xe hyperpolarizer device, with only a minor reduction in maximum achievable %P(Xe) and with greater consistency over a larger number of SEOP cell refill processes at a similar polarization lifetime duration (avg. T(1) = 82.4 min, standard deviation σ(T)(1) = 10.8 min). Additionally, the effects of varying SEOP jacket temperatures, distribution of Rb metal, and preparation and operation of the fluid path are quantified in the context of device installation, performance optimization and maintenance to consistently produce high (129)Xe polarization values, build-up rates (T(b) as low as 6 min) and lifetimes over the course of a typical high-throughput (129)Xe polarization SEOP cell life cycle. The results presented further demonstrate the significant potential for hyperpolarized (129)Xe contrast agent in imaging and bio-sensing applications on a clinical scale. |
format | Online Article Text |
id | pubmed-8879294 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-88792942022-02-26 Pilot Quality-Assurance Study of a Third-Generation Batch-Mode Clinical-Scale Automated Xenon-129 Hyperpolarizer Birchall, Jonathan R. Chowdhury, Md Raduanul H. Nikolaou, Panayiotis Chekmenev, Yuri A. Shcherbakov, Anton Barlow, Michael J. Goodson, Boyd M. Chekmenev, Eduard Y. Molecules Article We present a pilot quality assurance (QA) study of a clinical-scale, automated, third-generation (GEN-3) (129)Xe hyperpolarizer employing batch-mode spin-exchange optical pumping (SEOP) with high-Xe densities (50% natural abundance Xe and 50% N(2) in ~2.6 atm total pressure sourced from Nova Gas Technologies) and rapid temperature ramping enabled by an aluminum heating jacket surrounding the 0.5 L SEOP cell. (129)Xe hyperpolarization was performed over the course of 700 gas loading cycles of the SEOP cell, simulating long-term hyperpolarized contrast agent production in a clinical lung imaging setting. High levels of (129)Xe polarization (avg. %P(Xe) = 51.0% with standard deviation σ(P)(Xe) = 3.0%) were recorded with fast (129)Xe polarization build-up time constants (avg. T(b) = 25.1 min with standard deviation σ(T)(b) = 3.1 min) across the first 500 SEOP cell refills, using moderate temperatures of 75 °C. These results demonstrate a more than 2-fold increase in build-up rate relative to previously demonstrated results in a comparable QA study on a second-generation (GEN-2) (129)Xe hyperpolarizer device, with only a minor reduction in maximum achievable %P(Xe) and with greater consistency over a larger number of SEOP cell refill processes at a similar polarization lifetime duration (avg. T(1) = 82.4 min, standard deviation σ(T)(1) = 10.8 min). Additionally, the effects of varying SEOP jacket temperatures, distribution of Rb metal, and preparation and operation of the fluid path are quantified in the context of device installation, performance optimization and maintenance to consistently produce high (129)Xe polarization values, build-up rates (T(b) as low as 6 min) and lifetimes over the course of a typical high-throughput (129)Xe polarization SEOP cell life cycle. The results presented further demonstrate the significant potential for hyperpolarized (129)Xe contrast agent in imaging and bio-sensing applications on a clinical scale. MDPI 2022-02-16 /pmc/articles/PMC8879294/ /pubmed/35209116 http://dx.doi.org/10.3390/molecules27041327 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Birchall, Jonathan R. Chowdhury, Md Raduanul H. Nikolaou, Panayiotis Chekmenev, Yuri A. Shcherbakov, Anton Barlow, Michael J. Goodson, Boyd M. Chekmenev, Eduard Y. Pilot Quality-Assurance Study of a Third-Generation Batch-Mode Clinical-Scale Automated Xenon-129 Hyperpolarizer |
title | Pilot Quality-Assurance Study of a Third-Generation Batch-Mode Clinical-Scale Automated Xenon-129 Hyperpolarizer |
title_full | Pilot Quality-Assurance Study of a Third-Generation Batch-Mode Clinical-Scale Automated Xenon-129 Hyperpolarizer |
title_fullStr | Pilot Quality-Assurance Study of a Third-Generation Batch-Mode Clinical-Scale Automated Xenon-129 Hyperpolarizer |
title_full_unstemmed | Pilot Quality-Assurance Study of a Third-Generation Batch-Mode Clinical-Scale Automated Xenon-129 Hyperpolarizer |
title_short | Pilot Quality-Assurance Study of a Third-Generation Batch-Mode Clinical-Scale Automated Xenon-129 Hyperpolarizer |
title_sort | pilot quality-assurance study of a third-generation batch-mode clinical-scale automated xenon-129 hyperpolarizer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8879294/ https://www.ncbi.nlm.nih.gov/pubmed/35209116 http://dx.doi.org/10.3390/molecules27041327 |
work_keys_str_mv | AT birchalljonathanr pilotqualityassurancestudyofathirdgenerationbatchmodeclinicalscaleautomatedxenon129hyperpolarizer AT chowdhurymdraduanulh pilotqualityassurancestudyofathirdgenerationbatchmodeclinicalscaleautomatedxenon129hyperpolarizer AT nikolaoupanayiotis pilotqualityassurancestudyofathirdgenerationbatchmodeclinicalscaleautomatedxenon129hyperpolarizer AT chekmenevyuria pilotqualityassurancestudyofathirdgenerationbatchmodeclinicalscaleautomatedxenon129hyperpolarizer AT shcherbakovanton pilotqualityassurancestudyofathirdgenerationbatchmodeclinicalscaleautomatedxenon129hyperpolarizer AT barlowmichaelj pilotqualityassurancestudyofathirdgenerationbatchmodeclinicalscaleautomatedxenon129hyperpolarizer AT goodsonboydm pilotqualityassurancestudyofathirdgenerationbatchmodeclinicalscaleautomatedxenon129hyperpolarizer AT chekmeneveduardy pilotqualityassurancestudyofathirdgenerationbatchmodeclinicalscaleautomatedxenon129hyperpolarizer |